Therapy of chronic obstructive pulmonary disease.

[1]  P. Barnes.  New treatments for chronic obstructive pulmonary disease. , 2001, Current opinion in pharmacology.

[2]  Abdullah Alsaeedi,et al.  The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. , 2002, The American journal of medicine.

[3]  P. Barnes.  New treatments for copd , 2002, Nature Reviews Drug Discovery.

[4]  P. Barnes,et al.  Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[5]  P. Barnes,et al.  Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory cell and molecular biology.

[6]  M. Faulkner,et al.  The economic impact of chronic obstructive pulmonary disease , 2002, Expert opinion on pharmacotherapy.

[7]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[8]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[9]  D. Brooks,et al.  Nutritional supplementation for stable chronic obstructive pulmonary disease. , 2002, The Cochrane database of systematic reviews.

[10]  W. MacNee,et al.  Oxidative stress and lung inflammation in airways disease. , 2001, European journal of pharmacology.

[11]  P. Barnes.  Future Advances in COPD Therapy , 2001, Respiration.

[12]  C. Brambilla,et al.  Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study , 2001, The Lancet.

[13]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[14]  P. Anderson,et al.  Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial , 2001, The Lancet.

[15]  R. Wood‐Baker,et al.  Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. , 2001, The Cochrane database of systematic reviews.

[16]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[17]  H. Magnussen,et al.  In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. , 2001, Respiratory medicine.

[18]  A. Crockett,et al.  Domiciliary oxygen for chronic obstructive pulmonary disease. , 2005, The Cochrane database of systematic reviews.

[19]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[20]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[21]  Robert West,et al.  Smoking cessation guidelines for health professionals: an update , 2000, Thorax.

[22]  S. Peterson,et al.  The management of cor pulmonale. , 2000, Heart disease.

[23]  N. Lazzeri,et al.  Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. , 2000, American journal of respiratory and critical care medicine.

[24]  L. Stead,et al.  Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library , 2000, BMJ : British Medical Journal.

[25]  P. Barnes,et al.  Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[26]  D. Hansell,et al.  Effect of lung-volume-reduction surgery in patients with severe emphysema. , 2000, The New England journal of medicine.

[27]  P. Plant,et al.  Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial , 2000, The Lancet.

[28]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[29]  J. V. van Noord,et al.  A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease , 2000 .

[30]  P. Barnes.  Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[31]  P. Barnes,et al.  The pharmacological properties of tiotropium. , 2000, Chest.

[32]  N. Payne,et al.  Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial , 2000, The Lancet.

[33]  W. Bailey,et al.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.

[34]  K. Nichol,et al.  The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. , 1999, Archives of internal medicine.

[35]  R. Stockley.  Neutrophils and protease/antiprotease imbalance. , 1999, American journal of respiratory and critical care medicine.

[36]  W. Maziak,et al.  Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[37]  J. Wedzicha.  Domiciliary Oxygen Therapy Services: Clinical Guidelines and Advice for Prescribers , 1999, Journal of the Royal College of Physicians of London.

[38]  L. Davies,et al.  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 1999, The Lancet.

[39]  D. Postma,et al.  Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .

[40]  D. Niewoehner,et al.  Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.

[41]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[42]  Aker,et al.  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. , 1999, The New England journal of medicine.

[43]  K. Nichol,et al.  Relation between Influenza Vaccination and Outpatient Visits, Hospitalization, and Mortality in Elderly Persons with Chronic Lung Disease , 1999, Annals of Internal Medicine.

[44]  P. Barnes.  Molecular genetics of chronic obstructive pulmonary disease , 1999 .

[45]  V. Brusasco,et al.  Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. , 1999, American journal of respiratory and critical care medicine.

[46]  D. O’Donnell,et al.  Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[47]  M. Johnson,et al.  Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. , 1998, The European respiratory journal.

[48]  Alan D. Lopez,et al.  The global burden of disease, 1990–2020 , 1998, Nature Medicine.

[49]  R. Tamisier,et al.  Domiciliary nasal intermittent positive pressure ventilation in severe COPD: effects on lung function and quality of life. , 1997, The European respiratory journal.

[50]  P. Barnes,et al.  Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. , 1997, American journal of respiratory and critical care medicine.

[51]  Gordon H Guyatt,et al.  Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease , 1996, The Lancet.

[52]  S. Rennard,et al.  Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. , 1996, Chest.

[53]  L. Fabbri,et al.  Airway eosinophilia and expression of interleukin‐5 protein in asthma and in exacerbations of chronic bronchitis , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[54]  B. Celli,et al.  Long-term oxygen therapy. , 1995, The New England journal of medicine.

[55]  E. Vittinghoff,et al.  Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. , 1995, JAMA.

[56]  E. Tagaya,et al.  Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. , 1994, Thorax.

[57]  D. Mant,et al.  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation , 1994, The Lancet.

[58]  G H Guyatt,et al.  Respiratory muscle training in chronic airflow limitation: a meta-analysis. , 1992, The American review of respiratory disease.

[59]  N. Gross.  The influence of anticholinergic agents on treatment for bronchitis and emphysema. , 1991, The American journal of medicine.

[60]  M. Aubier,et al.  A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. , 1989, The New England journal of medicine.